LINK Medical is proud to have supported the clinical development of pHyph, Gedea Biotech’s novel antibiotic-free treatment for bacterial vaginosis, which has now received CE-marking under the EU MDR.
Bacterial vaginosis is one of the most common vaginal infections, often treated with antibiotics that may disrupt the microbiome and lead to frequent recurrences. pHyph represents a significant step forward for women’s health by offering a microbiome-friendly and effective treatment option.
Our contribution
LINK Medical has supported four clinical studies with pHyph. Two focused on bacterial vaginosis, while the other two studies investigated the product in vulvovaginal candidiasis. Through these studies, we provided broad clinical operations expertise and are proud to have contributed to bringing this important treatment closer to patients.
👉 Read the full press release from Gedea Biotech.